Experimental study on dynamic regulation of acetylcholine in striatum of rat parkinson disease model and behavior observation

Abstract

In order to explore the role of acetylcholine in the pathogenesis of Parkinson’s disease (PD), the changes in the concentration of acetylcholine (Ach) in the striatum, the apoptosis of substantia nigra cells, the ultrastructure and the changes of Nissl cells in rats during the morbidity of PD, and the corresponding behaviors in rats with PD were observed. Rat PD model was established by using the modified Thomas method. Eighty-one rats were randomly divided into normal control, sham operation and PD groups and their behavior features were observed at post-operative day (POD) 7, 14 and 21 as three subgroups (n=9 each). The concentration of Ach in the striatum was determined by using high-performance liquid chromatography. The apoptosis of substantia nigra cells was assayed by using TUNEL method. The ultrastructural changes in the substantia nigra were observed under the electron microscopy, and the survival of neurons in the substantia nigra area was examined by using Nissl staining. In PD group at POD 7 to 21, the damage in the substantia nigra area was gradually aggravated, the concentration of Ach, apoptosis rate and turns of rotation were gradually increased, and the number of Nissl cells was gradually reduced over the time as compared with the normal control and sham operation groups (all P<0.05). It was concluded that there exist dynamic changes in Ach concentration, ethology and apoptosis of the substantia nigra cells during the morbidity of PD, suggesting the contribution of apoptosis to the morbidity of PD, and critical role of Ach in the pathogenesis of PD.

Keywords

Parkinson’s disease acetylcholine / dopamine

References

[1] ChapmanM.A.. Does smoking reduce the risk of Parkinson’s disease throu gh stimulation of the ubiquitinproteasome system?. Med Hypotheses, 2009, 73(6): 887-891

[2] BohnenN.I., AlbinR.L.. Cholinergic denervation occurs early in Parkinson disease. Neurology, 2009, 73(4): 256-257

[3] VeenaJ., RaoB.S., SrikumarB.N.. Regulation of adult neurogenesis in the hippocampus by stress, acetylcholine and dopamine. J Nat Sci Biol Med, 2011, 2(1): 26-37

[4] YarnallA., RochesterL., BurnD.J.. The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord, 2011, 26(14): 2496-2503

[5] BaoX.M., ShuS.Y.. . A stereotaxic atlas of the rat brain, 1991, Beijing, The People’s Medical Publishing House, 1-2

[6] LacroixL.P., CeorlinL., ZocchiA.. Selective dopamine D (3) receptor antagonists enhance cortic al acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholin esterases. J Neurosci Methods, 2006, 157(1): 25-31

[7] TianQ., LinZ.Q., WangX.C., et al.. Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience, 2006, 126(2): 277-284

[8] Arruda PaesP.C., de MagalhaesL., CamilloM.A., et al.. Ionotropic glutamate receptors regulating labeled acetylcholine release from rat striatal tissue in vitro: possible involvement of receptor modulation in magnesium sensitivity. Neurosci Res, 2004, 49(3): 289-295

[9] XiangZ., ThompsonA.D., JonesC.K., et al.. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson’s disease. J Pharmacol Exp Ther, 2012, 340(3): 595-603

[10] RussoP., TalyA.. α7-nicotinic acetylcholine receptors: An old actor for new different roles. Curr Drug Targets, 2012, 13(5): 574-578

[11] HuangX., ChengZ., SuQ., et al.. Neuroprotection by nicotine against colchicine-induced apoptosis is mediated by PI3-kinase-Akt pathways. Int J Neurosci, 2012, 122(6): 324-332

[12] YuW., MechawarN., KranticS., et al.. α7 Nicotinic receptor activation reduces β-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling. J Neurochem, 2011, 119(4): 848-858

[13] QuartaD., CiruelaF., PatkarK.. Heteromeric nicotinic acetylcholine-dopaminecomplexes modulate striatal dopamine release. Neuropsychopharmacology, 2006, 170(1): 148-155

[14] RodeF., MunroG., HolstD., et al.. Positive allosteric modulation of α4β2 nAChR agonist induced behaviour. Brain Res, 2012, 1458: 67-75

[15] QuikM., WonnacottS.. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson’s disease. Pharmacol Rev, 2011, 63(4): 938-966